BOSTON--(BUSINESS WIRE)--Nov. 17, 2005--GlycoGenesys, Inc. (NASDAQ:GLGS), a biotechnology company, today announced it has initiated Roswell Park Cancer Institute, (RPCI) Buffalo, New York as a clinical site for its Phase I/II dose escalation trial in patients with multiple myeloma, the second most common blood cancer. The trial is designed to evaluate the safety and efficacy of the Company's drug candidate, GCS-100. RPCI was the first cancer research center in the nation and is a National Cancer Institute designated comprehensive cancer center. The Principal Investigator at this site is Asher A. Chanan-Khan, M.D. Dr. Chanan-Khan is an Attending Physician, Division of Lymphoma/Myeloma, RPCI and an Assistant Professor of Medicine, RPCI and School of Biomedical Sciences, State University of New York, Buffalo. Dr. Chanan-Khan's research interests include novel therapies for multiple myeloma and chronic lymphocytic leukemia (CLL).
